Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
30.45
Dollar change
0.00
Percentage change
0.00
%
Index- P/E12.01 EPS (ttm)2.54 Insider Own15.26% Shs Outstand446.69M Perf Week0.13%
Market Cap13.60B Forward P/E7.27 EPS next Y4.19 Insider Trans-2.11% Shs Float378.54M Perf Month-2.72%
Income1.13B PEG3.75 EPS next Q0.95 Inst Own68.62% Short Float3.34% Perf Quarter11.78%
Sales2.35B P/S5.78 EPS this Y-12.79% Inst Trans1.54% Short Ratio4.78 Perf Half Y13.87%
Book/sh14.61 P/B2.08 EPS next Y7.17% ROA6.84% Short Interest12.65M Perf Year-18.56%
Cash/sh1.11 P/C27.46 EPS next 5Y3.20% ROE18.68% 52W Range25.92 - 37.42 Perf YTD8.40%
Dividend Est.0.87 (2.86%) P/FCF4.49 EPS past 5Y2.23% ROI8.96% 52W High-18.63% Beta0.45
Dividend TTM0.81 (2.66%) Quick Ratio7.90 Sales past 5Y5.78% Gross Margin- 52W Low17.48% ATR (14)0.55
Dividend Ex-DateFeb 15, 2024 Current Ratio7.90 EPS Y/Y TTM2147.21% Oper. Margin63.38% RSI (14)56.14 Volatility1.25% 1.85%
Employees89 Debt/Eq0.94 Sales Y/Y TTM5.23% Profit Margin48.18% Recom1.22 Target Price42.37
Option/ShortYes / Yes LT Debt/Eq0.94 EPS Q/Q207.50% Payout31.57% Rel Volume0.00 Prev Close30.45
Sales Surprise-0.48% EPS Surprise13.74% Sales Q/Q5.30% EarningsFeb 15 BMO Avg Volume2.64M Price30.45
SMA201.11% SMA502.44% SMA2004.87% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jun-14-22Resumed UBS Buy $47
May-13-22Initiated Scotiabank Sector Outperform $53
Apr-27-22Initiated Goldman Buy $56
Apr-14-22Upgrade JP Morgan Neutral → Overweight $50
Apr-06-22Resumed Morgan Stanley Overweight $48
Oct-29-21Upgrade Citigroup Neutral → Buy $50
Jul-30-21Initiated Tigress Financial Buy $50
Nov-09-20Upgrade UBS Neutral → Buy $52 → $51
Jul-14-20Initiated Evercore ISI In-line
Jul-13-20Initiated UBS Neutral $52
Mar-17-24 08:50AM
Feb-28-24 04:15PM
Feb-20-24 12:45PM
Feb-17-24 12:15AM
Feb-16-24 03:30PM
09:45AM Loading…
09:45AM
12:04AM
Feb-15-24 11:08PM
07:58AM
07:30AM
Jan-31-24 01:04AM
Jan-30-24 04:15PM
Jan-19-24 08:15AM
Jan-08-24 07:00AM
Dec-18-23 05:30AM
04:15PM Loading…
Nov-27-23 04:15PM
Nov-13-23 08:10AM
08:00AM
Nov-09-23 04:33PM
12:15AM
Nov-08-23 07:00AM
Oct-19-23 07:59AM
Oct-16-23 04:15PM
Oct-11-23 04:15PM
Sep-21-23 08:25AM
Sep-05-23 04:15PM
04:01PM
08:25AM
Aug-24-23 06:30AM
Aug-08-23 07:00AM
04:15PM Loading…
Jul-18-23 04:15PM
Jul-17-23 04:15PM
Jun-18-23 08:58AM
Jun-07-23 08:15AM
May-22-23 07:52PM
May-13-23 08:15AM
May-11-23 10:42AM
May-09-23 07:00AM
May-03-23 04:15PM
Apr-20-23 06:15AM
Apr-17-23 08:15AM
Apr-13-23 09:01AM
Apr-05-23 06:17AM
Mar-31-23 06:36AM
Mar-27-23 07:30AM
Mar-23-23 07:00AM
03:00AM
Mar-15-23 08:00AM
Mar-08-23 05:16AM
Mar-01-23 08:15AM
Feb-15-23 07:00AM
Feb-09-23 04:15PM
Feb-03-23 09:19AM
Jan-18-23 08:25AM
Jan-12-23 05:01AM
Jan-09-23 09:25AM
09:15AM
09:05AM
08:30AM
06:35AM
Jan-04-23 04:15PM
Dec-15-22 08:15AM
Dec-08-22 05:23AM
Nov-28-22 04:26PM
Nov-09-22 08:49AM
08:10AM
Nov-08-22 07:00AM
Oct-18-22 08:30AM
Oct-17-22 08:30AM
Oct-12-22 04:15PM
07:00AM
Sep-09-22 09:15AM
Sep-06-22 04:15PM
Aug-13-22 08:05AM
Aug-04-22 07:00AM
Jul-15-22 08:15AM
Jul-14-22 06:04PM
08:58AM
08:30AM
Jul-13-22 04:25PM
04:05PM
Jul-04-22 02:44PM
Jun-30-22 06:06PM
08:42AM
07:31AM
07:15AM
Jun-27-22 02:12AM
Jun-08-22 08:30AM
Jun-04-22 08:22AM
May-23-22 08:30AM
May-17-22 07:00AM
May-05-22 07:00AM
May-04-22 03:32PM
Apr-18-22 08:00AM
Apr-13-22 08:00AM
Mar-29-22 08:00AM
Mar-15-22 09:48AM
Mar-03-22 08:30AM
Mar-01-22 03:34AM
Feb-25-22 09:01PM
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RIGGS RORY BDirectorJan 04 '24Sale27.5535,702983,50420,099Jan 04 05:16 PM
RIGGS RORY BDirectorJan 03 '24Sale27.79199,0985,532,27655,801Jan 04 05:16 PM
RIGGS RORY BDirectorJan 02 '24Sale28.52235,2006,707,081254,899Jan 04 05:16 PM
Avara Management Ltd10% OwnerDec 29 '23Sale28.0465,8031,845,4062,477,520Jan 03 04:31 PM
Avara Management Ltd10% OwnerDec 28 '23Sale28.20209,8635,918,9342,543,323Dec 29 04:29 PM
Avara Management Ltd10% OwnerDec 27 '23Sale28.0141,7291,168,7542,753,186Dec 29 04:29 PM
Avara Management Ltd10% OwnerDec 15 '23Sale28.0110,229286,4992,794,915Dec 19 04:30 PM
Avara Management Ltd10% OwnerDec 14 '23Sale28.91364,44110,534,2762,805,144Dec 15 04:31 PM
Avara Management Ltd10% OwnerDec 13 '23Sale28.95307,9358,916,0123,169,585Dec 15 04:31 PM
Coyne Terrance P.EVP & CFOAug 10 '23Sale30.7537,5001,153,091790,000Aug 11 05:00 PM
Coyne Terrance P.EVP & CFOAug 09 '23Sale30.7237,5001,151,936827,500Aug 11 05:00 PM
Coyne Terrance P.EVP & CFOJul 13 '23Sale30.9337,5001,159,958865,000Jul 14 06:09 PM
Coyne Terrance P.EVP & CFOJul 12 '23Sale31.0737,5001,165,256902,500Jul 14 06:09 PM
Legorreta Pablo G.CEO, Chairman of the BoardJun 28 '23Buy29.51130,0003,836,768600,000Jun 28 04:01 PM
Legorreta Pablo G.CEO, Chairman of the BoardJun 13 '23Buy32.7845,0001,474,902470,000Jun 13 04:01 PM
Legorreta Pablo G.CEO, Chairman of the BoardJun 12 '23Buy33.0045,0001,484,946425,000Jun 13 04:01 PM
Lloyd George W.EVP, Investments & CLOJun 06 '23Sale33.8279,0992,674,79630,000Jun 06 05:07 PM
Lloyd George W.EVP, Investments & CLOJun 05 '23Sale33.5419,215644,446109,099Jun 06 05:07 PM
Lloyd George W.EVP, Investments & CLOJun 02 '23Sale33.6493,9073,159,345120,000Jun 06 05:07 PM
Legorreta Pablo G.CEO, Chairman of the BoardMay 24 '23Buy32.25150,0004,837,440380,000May 24 06:45 PM
RIGGS RORY BDirectorMay 22 '23Sale32.821,750,00057,435,0006,762May 22 08:36 PM
Legorreta Pablo G.CEO, Chairman of the BoardMay 17 '23Buy32.9469,6122,293,096230,000May 17 06:41 PM
Legorreta Pablo G.CEO, Chairman of the BoardMay 16 '23Buy33.57160,3885,383,728160,388May 17 06:41 PM
RIGGS RORY BDirectorMar 30 '23Sale36.26130,0244,714,3451,456,762Mar 30 05:53 PM
Lloyd George W.EVP, Investments & CLOMar 29 '23Sale37.0312,779473,165212,221Mar 30 05:52 PM
RIGGS RORY BDirectorMar 29 '23Sale36.959,926366,7661,586,786Mar 30 05:53 PM